nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-084900B7·Framework v5.10·Pipeline v0.4·Evaluated 02 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Non-randomized or early-phase trial

Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.

Bernstein et al.Bernstein, Aygören-Pürsün, Cancian et al.·2025·Clinical and translational allergy·10.1002/clt2.70118 ↗

Primary claim

The KONFIDENT‐S OLE demonstrates that sebetralstat is a safe and effective oral on‐demand treatment for both laryngeal and abdominal HAE‐C1INH attacks, resulting in rapid onset of symptom relief.

Tentative · the uncontrolled open-label design cannot attribute observed symptom relief to sebetralstat
In brief

Sebetralstat’s extension study expands evidence on oral treatment during mucosal HAE attacks, but its uncontrolled design cannot establish efficacy.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

BACKGROUND: Hereditary angioedema (HAE-C1INH) attacks involving mucosal tissue may progress rapidly and often lead to substantial morbidity. Severe laryngeal attacks can be fatal without prompt administration of on-demand treatment. This prespecified interim analysis evaluated the safety and effectiveness of sebetralstat in laryngeal and abdominal attacks in the ongoing, 2-year, open-label extension KONFIDENT-S study (NCT05505916).

METHODS: Eligible participants ≥ 12 years with HAE-C1INH self-administered sebetralstat 600 mg film-coated tablets with an optional second dose after 3 h, if warranted.

PRIMARY OUTCOME: incidence of treatment-emergent adverse events (TEAEs).

SECONDARY OUTCOMES: times to beginning of symptom relief, reduction in severity, and complete resolution.

RESULTS: At data cutoff (Sep 14, 2024), 32 laryngeal (16 participants) and 533 abdominal only attacks (102 participants) were treated with sebetralstat. Seven (43.8%) participants with laryngeal attacks experienced 14 TEAEs whereas 36 (35.3%) participants with abdominal attacks experienced 91 TEAEs. No difficulty swallowing sebetralstat was reported. Median (IQR) time to treatment: 11.5 min (1.0-34.0) and 20.0 min (1.0-61.0) for laryngeal and abdominal attacks, respectively; time to beginning of symptom relief: 1.29 h (0.76-3.02) and 1.27 h (0.76-3.54); reduction in attack severity: 4.25 h (1.22 to > 12) and 3.52 h (1.26 to > 12); complete attack resolution: 12.69 h (5.11 to > 24) and 15.17 h (4.46 to > 24). Most mucosal attacks that achieved beginning of symptom relief within 12 h did so with a single dose of sebetralstat (laryngeal: 96.0%; abdominal: 95.8%). Conventional on-demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks.

CONCLUSION: Oral sebetralstat enabled rapid treatment of laryngeal and abdominal attacks of all severities, was well tolerated, and provided early symptom relief.

Key Claims

Primary finding · Tentative

The KONFIDENT‐S OLE demonstrates that sebetralstat is a safe and effective oral on‐demand treatment for both laryngeal and abdominal HAE‐C1INH attacks, resulting in rapid onset of symptom relief.

the uncontrolled open-label design cannot attribute observed symptom relief to sebetralstat

Conclusions
Quote verified
Secondary · Supported

No participants reported difficulty swallowing sebetralstat during laryngeal or abdominal attacks.

an observed feasibility finding limited by unspecified collection methods and few severe laryngeal attacks

Results, Safety and Tolerability
Quote verified
Secondary · Supported

Most of the attacks affecting the larynx (96.0%) and abdominal attacks (95.8%) that achieved beginning of symptom relief within 12 h did so with a single dose of sebetralstat.

a descriptive result conditional on observed relief within 12 hours, without a controlled estimate of single-dose efficacy

Results, Effectiveness
Quote verified
Secondary · Supported

Seven (43.8%) participants with laryngeal attacks experienced 14 TEAEs whereas 36 (35.3%) participants with abdominal attacks experienced 91 TEAEs.

descriptive participant-level counts without clear attack-linked attribution or exposure-adjusted rates

Abstract; Results, Safety and Tolerability
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Expanded prospective evidence for mucosal attacks

The analysis includes 32 laryngeal and 533 abdominal attacks, expanding the earlier interim dataset and addressing documented concerns about oral administration during mucosal swelling.

↳ Introduction, final paragraphs; Results, Attack Characteristics

#methodological rigour

Defined endpoints and scheduled electronic diaries

The prespecified interim analysis defines symptom-relief, severity-reduction, and resolution endpoints and specifies electronic-diary assessment intervals. Post hoc outcomes are explicitly identified.

↳ Materials and Methods, Study Endpoints

#positioning

Prior evidence and comparison limits addressed

The Introduction situates the analysis against randomized trials and concerns about oral dosing. The Discussion explains how population, severity, and endpoint differences restrict comparisons with injectable therapies.

↳ Introduction; Discussion, cross-study comparisons

Limitations

#methodological rigour

Uncontrolled observations cannot establish treatment efficacy

The extension lacks a concurrent comparator, while symptom outcomes are participant-reported. Its conclusion that treatment effectiveness is demonstrated exceeds what the observed trajectories identify.

↳ Materials and Methods, Statistics; Discussion, final paragraph; Conclusions

#methodological rigour

Adverse event collection method remains unspecified

Safety is the primary outcome, but the Methods does not explain how adverse events were systematically elicited. Event counts, grades, serious events, and discontinuations are reported without resolving that collection-method gap.

↳ Materials and Methods, Study Endpoints; Results, Safety and Tolerability

#application pathway

Laryngeal evidence rests on few participants

Only 16 participants contributed 32 laryngeal attacks, with locations reported without clinical confirmation. This limits extrapolation to broader and severe laryngeal presentations.

↳ Results, Participants and Attack Characteristics; Discussion, final paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The extension adds prospective observations on oral dosing during mucosal attacks, including no reported swallowing difficulty and a larger laryngeal dataset than the earlier interim analysis. Defined patient-reported endpoints and scheduled diaries make the descriptive outcomes interpretable. However, the absence of a comparator prevents attribution of symptom improvement to treatment, and the Methods leaves systematic adverse-event collection unspecified despite safety being primary. The Discussion appropriately qualifies cross-study comparisons but does not carry its acknowledged no-control limitation into the final effectiveness conclusion.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.7±0.1

Contribution
3.5

The analysis expands prospective mucosal-attack observations and directly addresses concerns about oral administration during swelling. Its advance is descriptive and incremental, with only 16 participants contributing laryngeal attacks and cumulative overlap with the earlier interim analysis.

Introduction, final two paragraphs; Results, Participants and Attack Characteristics
Methodological Rigour
2.0

Defined diary endpoints, a prespecified interim structure, and participant-level safety reporting support assessment of observed outcomes. The binding score reflects two distinct failures: efficacy inference without a comparator and an unspecified systematic adverse-event collection method despite safety being primary.

Materials and Methods, Study Endpoints and Statistics; Conclusions
Reporting
3.3

The paper separates safety, prespecified effectiveness endpoints, and post hoc analyses, with interpretable outcome definitions and units. Headline wording nevertheless attributes effectiveness to treatment more strongly than the uncontrolled observations permit.

Materials and Methods, Study Endpoints; Abstract, Conclusion; Conclusions
Positioning
2.8

The paper engages prior randomized trials, oral-administration concerns, and limitations of cross-study comparisons. Its final effectiveness conclusion contradicts the acknowledged inability of an uncontrolled extension to isolate treatment effects.

Introduction; Discussion, cross-study comparisons and final paragraph; Conclusions

Lower confidence on Contribution, Methodological Rigour — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

The supplied main text does not declare ethics approval or the consent process for the interventional study, which included adolescents. Trial registration, funding, conflicts of interest, and restricted data availability are disclosed.

Conflict of interest: declared · Ethics approval: not stated · Preregistration: declared · Data availability: declared

Reference IntegrityClean

33 references in manuscript 30 of 30 checkable references found in an index 3 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 02 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The finding is supported by a large open-label extension across 72 sites in 23 countries with 565 mucosal attacks, corroborating the Phase 3 trial, though without a control group.

From the paper
“sebetralstat is a safe and effective oral on-demand treatment for both laryngeal and abdominal HAE-C1INH attacks, resulting in rapid onset of symptom relief”

The paper names the treatment use and the population (people living with HAE-C1INH who self-administer on-demand therapy) that would act on these findings, though the drug is already approved.

Pathway

People living with HAE-C1INH and their treating clinicians adopt oral sebetralstat for rapid self-treatment of laryngeal and abdominal attacks, replacing delayed injectable therapies.

Barrier

The open-label, uncontrolled design with a relatively small number of laryngeal attacks limits certainty, and indirect comparisons with injectable treatments are constrained by differing endpoints and populations.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  2. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats
  3. CRISPR-Based Therapy for Hereditary Angioedema

    Cohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine

    Primary claim

    NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.

    Tentative
    Evidence Score
    3.6±0.1
    Reliability
    Caveats

How the rubric works →